Citro Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Citro Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $8.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Citro Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $8.8K Trade | TransData Nexus

Citro Pharma Private Limited

Indian Pharmaceutical Exporter · Biologics & Immunotherapy Specialist · $8.8K Total Trade · DGFT Verified

Citro Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $8.8K across 2 products in 2 therapeutic categories. Based on 7 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Etanercept ($6.0K), Axitinib ($2.8K), .

Citro Pharma Private Limited — Export Portfolio & Destination Treemap

Citro Pharma Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Citro Pharma Private Limited? — Company Overview & Market Position

Citro Pharma Private Limited, incorporated on October 14, 2016, is a private pharmaceutical company based in Bangalore, Karnataka, India. The company is registered under the Corporate Identification Number (CIN) U24230KA2016PTC097166. Its authorized and paid-up capital stands at ₹100,000 each. The registered office is located at No. 2/A, 4th Main Shampura, K G Halli, Bangalore, Karnataka, 560045.

Citro Pharma specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's export activities are primarily focused on biologics and immunotherapy products, with a notable presence in the advanced oncology therapeutic category. In the fiscal year 2022, Citro Pharma reported a total export value of $9,000 USD, encompassing seven shipments across two therapeutic categories. The top five exported products include Etanercept and Axitinib, with Etanercept accounting for $6,000 USD and Axitinib for $3,000 USD. The company's portfolio is highly concentrated, with the top five products comprising 100% of its export value.

What Does Citro Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Etanercept$6.0K

Product Portfolio — Top 2 by Export Value

Citro Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Etanercept	Biologics & Immunotherapy	$6.0K	3	0.0%	7
2	Axitinib	Advanced Oncology	$2.8K	4	3.0%	9

Citro Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $8.8K. The top category is Biologics & Immunotherapy (68.0% of portfolio), followed by Advanced Oncology (32.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Citro Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Citro Pharma operates a state-of-the-art manufacturing facility spanning 7,000 square meters, equipped with modern equipment and adhering to current Good Manufacturing Practice (cGMP) standards. The facility is designed to produce both liquid and lyophilized products, including injectable formulations, oncology drugs, biosimilars, and vaccines. It features a fully automated system compliant with GAMP-4 guidelines, ensuring high-quality production processes. The manufacturing plant has been validated through successful inspections by regulatory bodies such as the UK MHRA, Australia TGA, PICS, MCC South Africa, and Canada Health, resulting in cGMP compliance and certifications.

3Key Leadership

The leadership team at Citro Pharma comprises directors Shaikh Mukhtar Ahmed, Mukhtar Ahmed, and Ashfaq Ahmed, who have been associated with the company since its inception on October 14, 2016. While specific roles such as CEO, Managing Director, and CFO are not explicitly detailed in the available sources, the directors play a pivotal role in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Citro Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Citro Pharma's export activities are primarily focused on biologics and immunotherapy products, with a notable presence in the advanced oncology therapeutic category. In the fiscal year 2022, the company reported a total export value of $9,000 USD, encompassing seven shipments across two therapeutic categories. The top five exported products include Etanercept and Axitinib, with Etanercept accounting for $6,000 USD and Axitinib for $3,000 USD. The company's portfolio is highly concentrated, with the top five products comprising 100% of its export value.

2Emerging Markets

Citro Pharma has established a significant presence in emerging markets, particularly in regions such as Southeast Asia, the Middle East, and Africa. The company's manufacturing facility in Southeast Asia and the Middle East spans 7,000 square meters and is designed to produce injectable formulations, oncology drugs, biosimilars, and vaccines. This strategic positioning enables Citro Pharma to cater to the healthcare needs of these regions effectively.

3Geographic Strategy

Citro Pharma's geographic strategy involves a focused approach on emerging markets, including Southeast Asia, the Middle East, and Africa. The establishment of a manufacturing facility in these regions allows the company to meet the growing demand for affordable and high-quality pharmaceutical products. This strategic positioning helps mitigate concentration risk by diversifying the company's market presence and aligning with global healthcare needs.

Citro Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Citro Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. The company's manufacturing facility has been validated through successful inspections by regulatory bodies such as the UK MHRA, Australia TGA, PICS, MCC South Africa, and Canada Health, resulting in cGMP compliance and certifications.

2WHO & EU GMP

Citro Pharma's manufacturing facility has been validated through successful inspections by regulatory bodies such as the UK MHRA, Australia TGA, PICS, MCC South Africa, and Canada Health, resulting in cGMP compliance and certifications. However, specific details regarding WHO prequalification and EU GMP certificates are not available in the provided sources.

3CDSCO & Indian Regulatory

Specific details regarding Citro Pharma's CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not available in the provided sources. The company's manufacturing facility has been validated through successful inspections by regulatory bodies such as the UK MHRA, Australia TGA, PICS, MCC South Africa, and Canada Health, resulting in cGMP compliance and certifications.

Citro Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Citro Pharma operates in the competitive pharmaceutical industry, focusing on biologics, immunotherapy, and oncology products. While specific competitors in overlapping categories are not detailed in the provided sources, the company's emphasis on high-quality, affordable medicines positions it to compete effectively in both regulated and emerging markets. The establishment of manufacturing facilities in strategic locations enhances its ability to meet global healthcare needs and respond to market demands.

2Key Differentiators

Citro Pharma's key differentiators include its state-of-the-art manufacturing facility adhering to cGMP standards, strategic geographic positioning in emerging markets, and a focused product portfolio in biologics, immunotherapy, and oncology. The company's commitment to quality and affordability enables it to meet the diverse healthcare needs of various regions effectively.

3Strategic Position

Citro Pharma's current strategic direction focuses on the manufacturing and export of biologics, immunotherapy, and oncology products, with a strong emphasis on emerging markets. The establishment of manufacturing facilities in Southeast Asia and the Middle East aligns with the company's goal to provide affordable and high-quality medicines globally. Future outlooks suggest continued expansion in these regions, leveraging strategic partnerships and adhering to international regulatory standards to enhance market presence.

Buyer Due Diligence Brief — Evaluating Citro Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Citro Pharma demonstrates a strong track record in pharmaceutical manufacturing, with a focus on biologics, immunotherapy, and oncology products. The company's manufacturing facility is equipped with modern equipment and adheres to cGMP standards, ensuring high-quality production processes. The facility has been validated through successful inspections by regulatory bodies such as the UK MHRA, Australia TGA, PICS, MCC South Africa, and Canada Health, resulting in cGMP compliance and certifications.

2Certifications to Verify

Importers should verify the following certifications when considering Citro Pharma as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice (WHO-GMP) certification to ensure adherence to international manufacturing standards.

Frequently Asked Questions — Citro Pharma Private Limited

How many pharmaceutical products does Citro Pharma Private Limited export from India?

Citro Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Etanercept ($6.0K), Axitinib ($2.8K). Total export value is $8.8K.

What is Citro Pharma Private Limited's total pharmaceutical export value?

Citro Pharma Private Limited's total pharmaceutical export value is $8.8K, based on 7 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Citro Pharma Private Limited cover?

Citro Pharma Private Limited exports across 2 therapeutic categories. The largest are Biologics & Immunotherapy (68.0%, 1 products), Advanced Oncology (32.0%, 1 products).

Get Full Citro Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.